Gonadal dysfunction in male long-term survivors of malignant lymphoma

ars møller Pedersen0 个研究点目标入组 150 人开始时间: 2020年6月16日最近更新: 2022年4月4日

适应症

试验速览

暂无简介。

•Age 18-65 years at inclusion
•Verified diagnosis of de novo DLBCL or classical HL diagnosed between april 2013 and april 2018 according to WHO classification.
•Disease in complete remission for at least 2 years at inclusion.
•Completed curative intent first line treatment with anthracycline-containing chemotherapy with or without consolidating radiotherapy
•Literate in Danish
•Serum testosterone level below age-adjusted reference level.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 7
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Concurrent low-grade lymphoma
•Current or prior lymphoma of the central nervous system (CNS)
•Current or prior lymohoma of the testes
•Verified prostate cancer, cancer of the mammae, primary liver cancer-related, polycythaemia vera
•Mental or physical conditions that are expected to prevent the necessary compliance and/or adherence in relation to the study procedures
•Contraindications for the treatment with testosterone: PSA > 3 ng/ml, Hct > 0,49
•Treatment with second line chemotherapy or high dose therapy.
•Current or prior anabolic steroid abuse
•Known sexual dysfunction prior to enrolment.

发起方

ars møller Pedersen